Reuters: A panel of outside experts to the FDA, including David Blumenthal, assistant professor of medicine, unanimously voted against an experimental drug to prevent gout flares, based on trials that tested the drug for only 16 weeks. “A lot of the patients where we envision using this drug are going to take it for longer than 16 weeks. It’s hard for me to allow patients to be exposed (without longer safety data),” he said.
Medicine’s David Blumenthal sits on FDA expert panel reviewing gout drug
- Baker-Nord Center Director Peter Knox weighs in on importance of viewing war through humanistic lens
- MythBusters’ Adam Savage visits Sears think[box], meets with student inventor
- University community members honored for contributions to diversity, inclusion
- Engineering’s Alp Sehirlioglu recognized by alma mater with young alumnus award
- CWRU announces appointment of three executives to Board of Trustees